Merck KGaA (XTER:MRK)
€ 154.5 -1 (-0.64%) Market Cap: 67.17 Bil Enterprise Value: 75.03 Bil PE Ratio: 23.96 PB Ratio: 2.53 GF Score: 89/100

Merck KGaA R&D Update Call Transcript

Nov 22, 2021 / 01:00PM GMT
Release Date Price: €221.3 (+0.14%)
Operator

Dear ladies and gentlemen, welcome to the Merck R&D Update Call. (Operator Instructions) May I now hand you over to Constantin Fest, Head of Investor Relations, who will lead you through this conference. Please go ahead, sir.

Constantin Fest
MERCK Kommanditgesellschaft auf Aktien - Head of IR

Thank you, Alan. Dear ladies and gentlemen, a very warm welcome to this 2021 Merck R&D Update Call. My name is Constantin Fest, and I'm Head of Investor Relations here at Merck. I'm delighted also to have with me here today, Danny Bar-Zohar, Head of Development; Joern-Peter Halle, Head of Research; as well as Andrew Paterson, Chief Marketing Officer.

For the Q&A part of this call, we will also be joined by Andree Blaukat, Head of Research Oncology, Amy Kao, Head of Research Immunology; Jan Klatt, Head of Development Neurology & Immunology; as well as Victoria Zazulina, Head of Development Oncology.

We will now guide you through the key slides of this presentation. This will be then followed by a Q&A for you to ask all your questions.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot